Fundz

Ensysce acquires Cy Biopharma for $77 million

PUBLIC · ENSCAug 07, 2026

Acquiring Company

Ensysce Biosciences

Acquired Company

Cy Biopharma

La JollaManufacturingBiotechnologyHealthcareHardwareFinancial ServicesFinanceFintechLendingBankingBiotechnologyHealth CarePharmaceuticalBiopharma

Description

Ensysce Biosciences has acquired Cy Biopharma for USD 77 million to enhance its pain therapeutics portfolio. With this acquisition, Ensysce shifts from an opioid focus to include neuroplastogenic therapies for complex regional pain syndrome. Former Cy shareholders will hold approximately 75% of the combined entity, effectively integrating Cy's pipeline into Ensysce.

Company Information

Company

Ensysce Biosciences

Location

7946 IVANHOE AVE

La Jolla, California, United States

About

Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses.

Fundz sees it the moment Ensysce Biosciences makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Lynn
Likely contact at this company
••••••••@••••••••

See Lynn's verified email →

Andrew
Senior decision-maker at this company
••••••••@••••••••

See Andrew's verified email →

Paul
Likely contact at this company
••••••••@••••••••

See Paul's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Ensysce Biosciences's next move

Learn about Strategic plan

Frequently asked

Who acquired Cy Biopharma?

Cy Biopharma was acquired by Ensysce Biosciences, based in La Jolla. The deal was reported on August 7, 2026. Ensysce Biosciences, Inc. Ensysce Biosciences is publicly traded (ENSC) and operates in Manufacturing.

When did Ensysce Biosciences acquire Cy Biopharma?

Ensysce Biosciences's acquisition of Cy Biopharma was reported on August 7, 2026. Ensysce Biosciences has acquired Cy Biopharma for USD 77 million to enhance its pain therapeutics portfolio. With this acquisition, Ensysce shifts from an opioid focus to include neuroplastogenic therapies for complex regional pain syndrome. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Cy Biopharma do?

Cy Biopharma is a biopharmaceutical firm developing therapies for pain conditions. They focus on neuroplastogenic approaches to treat chronic pain syndromes. Their lead asset is a neuroplastogenic receptor agonist for complex regional pain syndrome. It is privately held, operating in Biotechnology.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.